EPISKIN

Name

EPISKIN

Legal name

EPISKIN SA

Website

https://episkin.com

Company type

Private

Founded year

1997

Operating status

Operating

Ownership category

akta.pro rank

Product category

In Vitro Tissue Engineering and Reconstructed Human Tissue Models

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• In vitro tissue models
• Reconstructed human epidermis
• Alternative toxicity testing
• OECD validated assays
• Epithelial tissue engineering

Headquarters

HQ city

Lyon

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Reconstructed Human Tissue Products: EPISKIN generates revenue from the sale of its reconstructed human skin and epithelial tissue models. The company produces and sells a range of models including T-Skin (Full Thickness), SkinEthic RHE, RHE-LC, RHPE, HCE, HO2E, HGE, HBE, and HVE. These are sold as ready-to-use in vitro tissue models in various formats including 6-well plates, HTS 24-well plates, and HTS 96-well plates.
2. Training Services: EPISKIN Academy provides paid training sessions at the Lyon facility, offering one-and-a-half day courses covering reconstructed model usage, validated protocol implementation (OECD TG431, TG439), and hands-on exercises. Sessions are limited to 4 trainees for personalized interaction. Over 1,600 experts trained worldwide across 72 training sessions since 2012.
3. Customized Testing Services: EPISKIN offers customized testing strategies and dedicated customer service for designing innovative protocols. The customer service team brings 25 years of internal expertise in producing and using the models to assist clients in specific testing needs.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

EPISKIN manufactures and sells patented in vitro reconstructed human tissue models, including full-thickness skin (T-Skin) and multiple epithelial tissues (SkinEthic RHE, RHE-LC, RHPE, HCE, HO2E, HGE, HBE, HVE), produced in ISO6 clean rooms via proprietary air-liquid-interface cell-culture processes. The company also provides EPISKIN Academy training services and customized testing protocols validated under OECD Test Guidelines.

Product overview

EPISKIN is a world leader in tissue engineering offering a comprehensive portfolio of human reconstructed tissues for in vitro testing. The product portfolio centers on eight distinct epithelial models: T-Skin (full thickness skin model), SkinEthic RHE (human epidermis), SkinEthic RHE-LC (epidermis with Langerhans cells), SkinEthic RHPE (pigmented epidermis), SkinEthic HCE (corneal epithelium), SkinEthic HO2E (oesophageal epithelium), SkinEthic HGE (gingival epithelium), SkinEthic HBE (bladder epithelium), and SkinEthic HVE (vaginal epithelium). These models support safety and efficacy evaluation for cosmetics, pharmaceutical, and chemical industries. The company also provides EPISKIN Academy for training and EPISKIN TV for educational content. All models are produced in ISO 9001 certified facilities with validated protocols aligned to OECD Test Guidelines.

Differentiator

Problem solved

Functional benefit

Brands

• SkinEthic: Product line of reconstructed human epithelial models including RHE, RHE-LC, RHPE, HCE, HO2E, HGE, HBE, and HVE for various testing applications.
• T-Skin
• EPISKIN Academy

Products and services

• T-Skin / Human Full Thickness Skin Model

Quantifiable outcome

• 85% overall accuracy in skin irritation testing validated by ECVAM (80% specificity, 90% sensitivity)
• +2 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature13 records

Partnerships

Four partnerships are on record, tiered core and regional.

• L'Oréal Research & InnovationcoreStrategic or Co-development PartnerEPISKIN is a subsidiary of L'Oréal, operating as a separate company (EPISKIN SA) while maintaining close ties to L'Oréal Research & Innovation. L'Oréal developed many of the core technologies and validated test methods including SkinEthic HCE EIT and HCE Time-to-Toxicity. EPISKIN is branded as 'Episkin / L'Oréal Research & Innovation' on its website. The company benefits from L'Oréal's 25+ years of tissue engineering expertise and R&D infrastructure.
• Nikoderm Research Co, LtdregionalChannel Partner/ Reseller/ DistributorAuthorized partner for EPISKIN products in Japan. Located at 1-6-14 Azuchimachi, Chuo-ku, Osaka City, Osaka 541-0052, Japan. Phone: 06-6125-3501. Contact: [email protected]. Website: www.nikoderm.com/
• Krishgen BiosystemsregionalChannel Partner/ Reseller/ DistributorAuthorized partner for EPISKIN products in India. Located at 318/319 Shah & Nahar Industrial Estate, Worli 400018, Mumbai, India. Phone: (022) 49198700. Website: www.krishgen.com
• Dowell C&IregionalChannel Partner/ Reseller/ DistributorAuthorized partner for EPISKIN products in Korea. Located at Yeojundo Center 415, Yulgok-ro 190, Jongno-gu, Seoul, 110-738, Korea. Phone: +82-2-536-1715. Contact: [email protected]

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Emerging players

• CN Bio Innovations: CN Bio develops microphysiological systems and organ-on-chip platforms for drug development and toxicology testing. It is an emerging alternative to EPISKIN's reconstructed tissue models for in vitro safety and efficacy testing.
• Emulate Inc. Emulate develops organ-on-chip technology that competes with traditional reconstructed tissue models like EPISKIN's for predictive toxicology applications. It represents an emerging alternative that could erode EPISKIN's market position as organ-on-chip gains regulatory acceptance.
• BICO (CELLINK): BICO is a bioconvergence company offering bioprinting and tissue engineering solutions that could complement or compete with EPISKIN's reconstructed tissue models, particularly in research and drug discovery applications.

Others

• Skin Analytics: Skin Analytics is a UK-based dermatology AI company. While operating in a different domain (clinical AI for skin lesion assessment), it serves the same dermatology research and pharmaceutical customer base as EPISKIN and represents an adjacent ecosystem participant.

Direct peers

• MatTek Corporation: MatTek produces EpiDerm, a reconstructed human epidermal model that is the most direct competitor to EPISKIN's SkinEthic RHE. Both supply OECD-validated in vitro skin models for irritation, corrosion, and other toxicology endpoints to cosmetics, pharmaceutical, and chemical industries.
• Stratatech (Mallinckrodt): Stratatech develops engineered human skin substitutes (StrataGraft) for both clinical wound healing and in vitro testing applications, overlapping with EPISKIN's tissue engineering expertise in reconstructed human skin models.

Broad incumbents

• Organogenesis Holdings: Organogenesis is a larger regenerative medicine company focused on advanced wound care and surgical biologics using skin and tissue technologies. While mainly commercial, its tissue engineering capabilities overlap with EPISKIN's broader portfolio of skin and epithelial models.
• Eurofins Scientific: Eurofins is a global contract testing CRO that serves the same cosmetics, pharmaceutical, and chemical industries EPISKIN serves. While not a tissue model producer, it is a major buyer of in vitro models and offers downstream testing services built on platforms like EPISKIN's.
• Charles River Laboratories: Charles River is a major CRO that provides preclinical and toxicology services, including in vitro testing for cosmetics and chemicals. It uses reconstructed tissue models from suppliers like EPISKIN for its contract testing service offerings.
• Labcorp Drug Development: Labcorp is a major CRO that purchases in vitro skin and epithelial models like EPISKIN's for pharmaceutical and chemical safety testing. Its central laboratory and early development services overlap with EPISKIN's downstream customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/episkin-snc

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EPISKIN